Testosterone cypionate
Testosterone cypionate, long-chain injectable ester
Written by Aaron CuhaReviewed Sep 2026
Also known as: Depo-Testosterone, Test C, Cypionate
The most prescribed injectable testosterone in the United States. Its eight-day half-life is why a single weekly shot produces a peak and a crash, and why splitting the same total flattens the curve.
Overview
This is the vial most people are handed. It is testosterone with an eight-carbon cypionate ester attached, dissolved in oil, which slows release from the injection site and turns a hormone that would clear in hours into one dosed weekly.
The practical question almost everyone has is not whether to take it but how often. The usual instruction is one injection a week, or sometimes one every two weeks, and the interval is frequently chosen out of habit. With a short-acting ester that choice determines the experience: a large dose at a long interval sends levels well above the target range in the first days and lets them fall toward or below it before the next one.
Splitting the same weekly total into two or three smaller injections flattens that curve. It does not change the dose. The evidence for this is pharmacokinetic reasoning plus clinical practice rather than a randomised trial, and the page says so.
Mechanism of action
Testosterone esterified at the 17-beta hydroxyl with cyclopentylpropionic acid, which makes it lipophilic enough to remain in an oil depot at the injection site. Tissue esterases cleave the ester gradually to release free testosterone, so the ester chain length governs the release rate rather than the activity. Once cleaved, the hormone is identical to endogenous testosterone and acts at the androgen receptor, with the same conversions to dihydrotestosterone by 5-alpha-reductase and to oestradiol by aromatase. Peak-to-trough variation across a dosing interval is a property of the ester and the interval, not of the molecule's potency.
Human evidence
Decades of approved use with well-characterised pharmacokinetics. The frequency question rests on that pharmacokinetics and on practice guidance rather than on a randomised comparison of schedules.
- Half-life roughly 8 days, which is what makes the dosing interval consequential rather than arbitrary.
- Larger doses at longer intervals produce greater swings in serum exposure across the cycle.
- Symptoms reported at the peak end include acne, oily skin, mood or sleep disturbance, breast tenderness and fluid retention. At the trough end, fatigue, reduced libido and erectile symptoms.
- Practice guidance is explicit that every-two-week dosing should not be the automatic default for a short-acting ester.
- The interval also determines when a blood level means anything. A level drawn at the wrong point in the cycle is worse than no level, and the guidance asks clinicians to document the ester, dose, route, interval, timing of the last injection and timing of the draw.
What this does not tell you: No randomised trial comparing split against single weekly dosing with symptom endpoints was located, so this is pharmacokinetic reasoning supported by practice guidance rather than trial evidence. It also says nothing about total dose: splitting delivers the prescribed amount more evenly and is not a reason to take more. Changing a schedule changes when bloodwork should be drawn, so it is a conversation with the prescriber rather than a private adjustment.
Reading the research record
The dosing interval is where most of the avoidable trouble lives, and the reasoning is simple. Testosterone cypionate and enanthate are short-acting esters. Give a large dose at a long interval and serum testosterone rises well above the target range in the first days and falls toward or below it before the next injection, so the same weekly total produces a very different experience depending on how it is split. A 2026 practice review states the position directly: every-two-week dosing remains convenient and should not be the automatic default for a short-acting injectable, weekly is often reasonable, and where a patient reports symptom cycling, early acne or oily skin, mood or sleep disturbance, breast tenderness, fluid retention, late-cycle fatigue or reduced libido, the problem may be dose timing and peak-to-trough variation rather than an inadequate weekly total. Splitting the same weekly amount across two or three injections flattens that curve.
Two honest limits. This is pharmacokinetic reasoning plus clinical practice, not a randomised trial of split against weekly dosing with symptom endpoints, and no such trial was located. And it changes nothing about the total dose: splitting is a way of delivering the amount you were prescribed more evenly, not a reason to take more. Anyone changing an injection schedule should tell the prescriber, because it also changes when bloodwork should be drawn, and a level measured at the wrong point in the cycle is worse than no level at all.
The evidence, charted
Fig. 1 · evidence composition
1of 2 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2023 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Review2026
Individualizing injectable testosterone replacement therapy in primary care: pharmacokinetics, symptom stability, safety monitoring, and injection interval
The direct treatment of the frequency question. Short-acting esters such as cypionate and enanthate produce meaningful changes in serum exposure across the dosing cycle, particularly at larger doses and longer intervals, which can create early peak-related symptoms and late-cycle return of hypogonadal symptoms and makes laboratory interpretation harder. Every-two-week dosing is convenient and should not be the automatic default. Weekly is often reasonable. Where symptom cycling persists, the issue may be dose timing and peak-to-trough variation rather than an inadequate total weekly dose. A narrative practice review, not a randomised comparison.
Cureus - Human2023
Cardiovascular safety of testosterone-replacement therapy
TRAVERSE, 5,246 men, no excess of cardiovascular death, heart attack or stroke against placebo. Included because it is the safety context for any testosterone ester, with the qualifier that TRAVERSE used a transdermal gel titrated to a defined range rather than an injectable.
New England Journal of Medicine
Frequently asked questions
Should I split my weekly dose into two or three injections?
The pharmacokinetics support it and the practice guidance says the interval should be a clinical decision rather than a habit. With an eight-day half-life, the same weekly total delivered in smaller more frequent injections produces a flatter curve, which is the point. What does not exist is a randomised trial of split against weekly with symptom endpoints, so treat this as well-reasoned rather than proven, and tell your prescriber, because it changes when your bloodwork should be drawn.
How do I know if my schedule is wrong for me?
Look for a pattern rather than a level. Acne, oily skin, irritability, poor sleep, breast tenderness or fluid retention in the first days after an injection, and fatigue, low libido or erectile symptoms in the last days before the next one, is the signature of peak-to-trough swing. That pattern suggests the timing rather than the amount is the problem.
When should blood be drawn?
At a point in the cycle you and your prescriber have agreed and recorded, along with the ester, dose, route, interval and the timing of your last injection. Without that context a testosterone result is close to uninterpretable, which is the specific reason the practice guidance asks for all of it to be documented.
Is cypionate better than enanthate?
No meaningful clinical difference has been established. The half-lives are close enough that the choice is usually driven by what is stocked and what the carrier oil is, which matters mainly to people who react to one of them.